Trade Stoke Therapeutics, Inc. - STOK CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.13
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.01)

Key Stats

• Prev. Close: 29.87
• Open: 29.71
• 1-Year Change: 51.12%
• Day's Range: 29.18 - 29.76

Trade Stoke Therapeutics, Inc. - STOK

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc. is a biotechnology company. It focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. It is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. It focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. It utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Stoke Therapeutics Inc revenues was not reported. Net loss increased 64% to $85.8M. Higher net loss reflects Research and development - Balancing val increase of 58% to $48M (expense), Stock-based Compensation in SGA increase from $3.9M to $10.2M (expense), General and administrative - Balancing increase of 28% to $21.7M (expense).